Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Operating Leases (2019 - 2025)

Gyre Therapeutics (GYRE) has disclosed Operating Leases for 7 consecutive years, with $303000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 65.76% to $303000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $303000.0 through Dec 2025, down 65.76% year-over-year, with the annual reading at $303000.0 for FY2025, 65.76% down from the prior year.
  • Operating Leases for Q4 2025 was $303000.0 at Gyre Therapeutics, down from $539000.0 in the prior quarter.
  • The five-year high for Operating Leases was $1.3 million in Q2 2024, with the low at $121000.0 in Q4 2022.
  • Average Operating Leases over 5 years is $642071.4, with a median of $660500.0 recorded in 2021.
  • The sharpest move saw Operating Leases crashed 70.34% in 2022, then skyrocketed 345.71% in 2025.
  • Over 5 years, Operating Leases stood at $408000.0 in 2021, then plummeted by 70.34% to $121000.0 in 2022, then surged by 64.46% to $199000.0 in 2023, then skyrocketed by 344.72% to $885000.0 in 2024, then crashed by 65.76% to $303000.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $303000.0, $539000.0, and $771000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.